Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: June 27, 2022

Details for Patent: 7,381,427

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,381,427 protect, and when does it expire?

Patent 7,381,427 protects ESKATA and is included in one NDA.

This patent has fourteen patent family members in thirteen countries.

Summary for Patent: 7,381,427

Title:	Seborrheic keratosis treatment
Abstract:	The subject of the present invention is seborrheic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation.
Inventor(s):	Ancira; Margaret (Phoenix, AZ), Miller; Mickey (Paradise Valley, AZ)
Assignee:	Miller; Mickey (Paradise Valley, AZ)
Application Number:	10/684,136
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 7,381,427

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	See Plans and Pricing	See Plans and Pricing				TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,381,427

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	397452	See Plans and Pricing
Australia	2007203283	See Plans and Pricing
Brazil	0207163	See Plans and Pricing
Canada	2437823	See Plans and Pricing
China	100508990	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Mallinckrodt

Johnson and Johnson

Baxter

Boehringer Ingelheim

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.